Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses

Paul Licciardi, Anne Balloch, F Russell, R Burton, J Lin, M NAHM, Edward (Kim) MULHOLLAND, Mimi Tang

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Background: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known.

    Objective: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax.

    Methods: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively.

    Results: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low.

    Conclusion: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries.

    Original languageEnglish
    Pages (from-to)794-800
    Number of pages7
    JournalJournal of Allergy and Clinical Immunology
    Volume129
    Issue number3
    DOIs
    Publication statusPublished - Mar 2012

    Fingerprint

    Pneumococcal Vaccines
    Developing Countries
    Antibody Formation
    Immunoglobulin G
    Serogroup
    Child Mortality
    Glycoconjugates
    Antibody Affinity
    Streptococcus pneumoniae
    Antibodies

    Cite this

    Licciardi, Paul ; Balloch, Anne ; Russell, F ; Burton, R ; Lin, J ; NAHM, M ; MULHOLLAND, Edward (Kim) ; Tang, Mimi. / Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. In: Journal of Allergy and Clinical Immunology. 2012 ; Vol. 129, No. 3. pp. 794-800.
    @article{e9c035ea5ed4420fa775032d54750a06,
    title = "Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses",
    abstract = "Background: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. Objective: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. Methods: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. Results: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30{\%} produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. Conclusion: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries.",
    author = "Paul Licciardi and Anne Balloch and F Russell and R Burton and J Lin and M NAHM and MULHOLLAND, {Edward (Kim)} and Mimi Tang",
    year = "2012",
    month = "3",
    doi = "10.1016/j.jaci.2011.11.043",
    language = "English",
    volume = "129",
    pages = "794--800",
    journal = "Journal of Allergy and Clinical Immunology",
    issn = "0091-6749",
    publisher = "Mosby International",
    number = "3",

    }

    Licciardi, P, Balloch, A, Russell, F, Burton, R, Lin, J, NAHM, M, MULHOLLAND, EK & Tang, M 2012, 'Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses', Journal of Allergy and Clinical Immunology, vol. 129, no. 3, pp. 794-800. https://doi.org/10.1016/j.jaci.2011.11.043

    Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. / Licciardi, Paul; Balloch, Anne; Russell, F; Burton, R; Lin, J; NAHM, M; MULHOLLAND, Edward (Kim); Tang, Mimi.

    In: Journal of Allergy and Clinical Immunology, Vol. 129, No. 3, 03.2012, p. 794-800.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses

    AU - Licciardi, Paul

    AU - Balloch, Anne

    AU - Russell, F

    AU - Burton, R

    AU - Lin, J

    AU - NAHM, M

    AU - MULHOLLAND, Edward (Kim)

    AU - Tang, Mimi

    PY - 2012/3

    Y1 - 2012/3

    N2 - Background: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. Objective: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. Methods: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. Results: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. Conclusion: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries.

    AB - Background: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. Objective: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. Methods: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. Results: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. Conclusion: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries.

    U2 - 10.1016/j.jaci.2011.11.043

    DO - 10.1016/j.jaci.2011.11.043

    M3 - Article

    VL - 129

    SP - 794

    EP - 800

    JO - Journal of Allergy and Clinical Immunology

    JF - Journal of Allergy and Clinical Immunology

    SN - 0091-6749

    IS - 3

    ER -